Versant Capital Management
KROS icon

Versant Capital Management’s Keros Therapeutics KROS Stock Holding History

Versant Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11K Buy
+969
New +$10.6K ﹤0.01% 2231
2026
Q2 		– Sell
-31
Closed -$342 – 2807
2026
Q1 		$342 Buy
+31
New +$479 ﹤0.01% 2741
2025
Q2 		– Sell
-643
Closed -$6.55K – 2685
2025
Q1 		$6.55K Buy
+643
New +$7.47K ﹤0.01% 1919

Other funds holding KROS

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Versant Capital Management's KROS Position: Q3 2026 in Review

Versant Capital Management opened a new position in Keros Therapeutics (KROS) in Q3 2026: 969 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #2231 among its holdings. This is a return to the name: Versant Capital Management previously reported a position in KROS as recently as Q1 2026.

Versant Capital Management first reported a position in KROS in Q1 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

  • Versant Capital Management held 969 shares of Keros Therapeutics worth $11K as of Q3 2026.
  • Keros Therapeutics was a new Versant Capital Management position in Q3 2026.
  • Keros Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2231 holding.
  • Versant Capital Management first reported a position in Keros Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.